Answers are grounded in this paper and cite their sources.
This review summarizes the current development and potential clinical positioning of ultra-LABAs, including their cardiovascular safety, for the treatment of COPD.
Aim. The treatment of chronic obstructive pulmonary disease (COPD) is generally based on the assumption of drug combinations in which 2 -agonists are commonly included. Ultra-LABAs were developed to induce a greater adherence to the treatment as a result of the simplification of treatment with the reduction of the daily dose to be taken. Material and methods. We analyzed the current literature data on 2-adrenergic agonists. The potential positioning of ultra-LABAs in the treatment of COPD and their cardiovascular safety is discussed according to the new information on the topics. Results and discussion. The novel fixed-dose combinations of ultra-LABAs with LAMAs and/or ICSs are examined, as well as the novel ultra-LABAs under clinical development and the ultra-LABAs in preclinical development.
No takes yet. Share an insight, caveat, or question.
PUXXEDU et al. (2017) conducted a review in Chronic Obstructive Pulmonary Disease (COPD). Ultra-LABAs was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: